Goldman Sachs raised the firm’s price target on Alkermes (ALKS) to $32 from $30 and keeps a Buy rating on the shares after its Q4 earnings beat and 2025 guidance. The results reflect continued build in investor focus and enthusiasm for the company’s opportunity set in therapeutics for sleep related disorders with their advancing pipeline of Orexin agonist assets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes outlook reflects underlying strength, says H.C. Wainwright
- Alkermes price target raised to $38 from $35 at TD Cowen
- Alkermes price target raised to $34 from $33 at BofA
- Alkermes: Stability with Limited Upside Amid Program Expectations and Competitive Pressures
- Alkermes plc Reports Strong 2024 Financial Results